Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Targeting the weight within: obesity pharmacotherapy in cardiovascular disease orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Targeting the weight within: obesity pharmacotherapy in cardiovascular disease ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Targeting the weight within: obesity pharmacotherapy in cardiovascular disease, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Targeting the weight within: obesity pharmacotherapy in cardiovascular disease in your area.
An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25
25.83
Oral semaglutide reduces risk of cardiovascular events
29.65
Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial
27.31
Results of SOUL Trial with Oral Semaglutide
28.66
SOUL trial shows oral semaglutide has positive CV benefits in type 2 diabetes
22.37
01375-3/asset/2a0aa5b3-9fde-4bd7-ad14-b865e6ec5eb5/main.assets/gr2_lrg.jpg)
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial
25.43
SOUL: Oral Semaglutide Cuts MACE by 14% in People with Type 2 Diabetes
25.62
